Literature DB >> 3386242

Biology and mode of action of pure antioestrogens.

A E Wakeling1, J Bowler.   

Abstract

The properties of a series of 7 alpha-alkyl analogues of oestradiol are described. Studies of chemical structure and activity in the immature rat uterotrophic/antiuterotrophic assay revealed that molecules containing a terminal functional group (acid, alcohol, amine, amide) linked to the steroid by a decamethylene bridge possess both oestradiol agonist and antagonist activity. However, certain amides, exemplified by the compound ICI 164,384 [N-n-butyl-11-(3,17 beta-dihydroxyoestra-1,3,5(10)-trien-7 alpha-yl)-N-methylundecanamide], were devoid of oestrogenic activity but possessed potent antioestrogenic activity. Comparison of receptor binding and biological potency of steroid 7 alpha- and 7 beta-isomers showed that activity is confined largely to the 7 alpha-isomer. Comparison of the effects of tamoxifen and ICI 164,384 on progesterone receptor (PR) concentration in the rat uterus showed that, unlike tamoxifen, ICI 164,384 did not induce PR and blocked induction of PR by oestradiol. Chronic treatment of mature female rats with ICI 164,384 led to an ovariectomy-like regression of the uterus without affecting LH secretion or the rate of growth. ICI 164,384 was also an effective antitumour agent in rats bearing carcinogen-induced mammary tumours.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386242     DOI: 10.1016/0022-4731(88)90086-6

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  16 in total

1.  Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro.

Authors:  N D Arbuckle; S Dauvois; M G Parker
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

2.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

Authors:  S Dauvois; P S Danielian; R White; M G Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  Action of "pure" antiestrogens in inhibiting estrogen receptor action.

Authors:  M G Parker
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; Y Merand; D Poirier; C Levesque; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

Review 5.  Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

Authors:  Irshad Ahmad; Shimy Mathew; Sofia Rahman
Journal:  RSC Med Chem       Date:  2020-03-06

6.  The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities.

Authors:  Kristi L Hoffman; Estrella A Foster; Carolyn L Smith
Journal:  Steroids       Date:  2012-02-02       Impact factor: 2.668

7.  Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.

Authors:  H Michna; M R Schneider; Y Nishino; M F el Etreby
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

8.  Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.

Authors:  A Mahfoudi; E Roulet; S Dauvois; M G Parker; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

9.  A protein that interacts with members of the nuclear hormone receptor family: identification and cDNA cloning.

Authors:  M Zeiner; U Gehring
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

10.  Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.

Authors:  Y Nishino; M R Schneider; H Michna
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.